Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JBIO NASDAQ:NERV NASDAQ:PHAR NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJBIOJade Biosciences$15.22+1.6%$20.92$6.57▼$28.00$739.41M1.44921,995 shs1.60 million shsNERVMinerva Neurosciences$4.74+2.4%$5.65$1.57▼$12.46$215.71M-0.18142,079 shs96,310 shsPHARPharming Group$12.59-1.6%$14.91$9.54▼$21.34$904M-0.0412,163 shs4,130 shsSPRYARS Pharmaceuticals$9.41+4.7%$8.33$6.66▼$18.90$892.74M0.941.77 million shs877,523 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJBIOJade Biosciences-11.57%-19.42%-41.96%+3.45%+1,497,999,900.00%NERVMinerva Neurosciences-6.65%-4.34%-21.26%-41.69%+153.14%PHARPharming Group+1.47%-2.29%-1.39%-23.22%+7.19%SPRYARS Pharmaceuticals+5.02%-4.67%+2.86%+1.47%-37.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJBIOJade Biosciences$15.22+1.6%$20.92$6.57▼$28.00$739.41M1.44921,995 shs1.60 million shsNERVMinerva Neurosciences$4.74+2.4%$5.65$1.57▼$12.46$215.71M-0.18142,079 shs96,310 shsPHARPharming Group$12.59-1.6%$14.91$9.54▼$21.34$904M-0.0412,163 shs4,130 shsSPRYARS Pharmaceuticals$9.41+4.7%$8.33$6.66▼$18.90$892.74M0.941.77 million shs877,523 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJBIOJade Biosciences-11.57%-19.42%-41.96%+3.45%+1,497,999,900.00%NERVMinerva Neurosciences-6.65%-4.34%-21.26%-41.69%+153.14%PHARPharming Group+1.47%-2.29%-1.39%-23.22%+7.19%SPRYARS Pharmaceuticals+5.02%-4.67%+2.86%+1.47%-37.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJBIOJade Biosciences 2.89Moderate Buy$47.43211.62% UpsideNERVMinerva Neurosciences 2.00Hold$10.50121.52% UpsidePHARPharming Group 2.40Hold$38.33204.47% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.60203.93% UpsideCurrent Analyst Ratings BreakdownLatest NERV, SPRY, JBIO, and PHAR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026JBIOJade Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.006/2/2026JBIOJade Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.006/2/2026JBIOJade Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $45.006/1/2026JBIOJade Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/1/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026JBIOJade Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $74.006/1/2026JBIOJade Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $55.005/28/2026SPRYARS Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $30.005/27/2026JBIOJade Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/15/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJBIOJade BiosciencesN/AN/AN/AN/A$6.74 per shareN/ANERVMinerva NeurosciencesN/AN/AN/AN/A($3.25) per shareN/APHARPharming Group$376.13M2.36$0.20 per share63.82$3.95 per share3.19SPRYARS Pharmaceuticals$84.28M11.09N/AN/A$1.16 per share8.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/ANERVMinerva Neurosciences-$293.42M-$29.16N/A0.98N/AN/AN/A-32.63%8/13/2026 (Estimated)PHARPharming Group$2.85M$0.1678.6919.37N/A3.30%4.64%2.55%7/30/2026 (Estimated)SPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)Latest NERV, SPRY, JBIO, and PHAR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million5/5/2026Q1 2026NERVMinerva Neurosciences-$0.13-$0.17-$0.04-$2.86N/AN/A3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million3/9/2026Q4 2025SPRYARS Pharmaceuticals-$0.42-$0.42N/A-$0.42$25.58 million$28.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJBIOJade BiosciencesN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJBIOJade BiosciencesN/A14.2914.29NERVMinerva NeurosciencesN/A17.6517.65PHARPharming Group0.352.632.06SPRYARS Pharmaceuticals2.794.944.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJBIOJade BiosciencesN/ANERVMinerva Neurosciences34.56%PHARPharming Group0.03%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipJBIOJade Biosciences23.06%NERVMinerva Neurosciences1.70%PHARPharming Group2.07%SPRYARS Pharmaceuticals33.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJBIOJade Biosciences2049.36 million37.98 millionN/ANERVMinerva Neurosciences946.59 million45.80 millionNot OptionablePHARPharming Group28070.62 million69.16 millionNot OptionableSPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableNERV, SPRY, JBIO, and PHAR HeadlinesRecent News About These CompaniesHow The Evolving Story For ARS Pharmaceuticals (SPRY) Could Shape Future ValuationJune 9 at 1:50 PM | finance.yahoo.comDrew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe AllergiesJune 4, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Rating of "Moderate Buy" by BrokeragesMay 29, 2026 | americanbankingnews.comWhy ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Up 5.30%May 20, 2026 | aaii.comAARS Pharmaceuticals: Still A Buy As Neffy Access ImprovesMay 20, 2026 | seekingalpha.comArs Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access programMay 16, 2026 | seekingalpha.comARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 16, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comARS Pharmaceuticals Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue EstimatesMay 15, 2026 | zacks.comARS Pharmaceuticals Reports Q1 2026 Financial Results Highlighting $22.7 Million in Revenue and Progress on neffy® CommercializationMay 15, 2026 | quiverquant.comQARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate UpdateMay 15, 2026 | globenewswire.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15, 2026 | benzinga.comARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsMay 15, 2026 | benzinga.comARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as PresidentMay 13, 2026 | globenewswire.comUBS Group AG Purchases 1,550,980 Shares of ARS Pharmaceuticals, Inc. $SPRYMay 11, 2026 | marketbeat.comARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comEarnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to DeclineMay 6, 2026 | zacks.comHow The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And ApprovalsMay 2, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?April 23, 2026 | zacks.comNorthland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation DriverApril 17, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026AI Can’t Reach the Real World Without These 3 StocksBy Thomas Hughes | May 27, 2026NERV, SPRY, JBIO, and PHAR Company DescriptionsJade Biosciences NASDAQ:JBIO$15.22 +0.24 (+1.60%) Closing price 04:00 PM EasternExtended Trading$15.21 -0.01 (-0.07%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Minerva Neurosciences NASDAQ:NERV$4.74 +0.11 (+2.38%) Closing price 04:00 PM EasternExtended Trading$4.70 -0.04 (-0.84%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Pharming Group NASDAQ:PHAR$12.59 -0.21 (-1.64%) Closing price 03:55 PM EasternExtended Trading$12.49 -0.10 (-0.79%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.ARS Pharmaceuticals NASDAQ:SPRY$9.41 +0.42 (+4.67%) Closing price 04:00 PM EasternExtended Trading$9.28 -0.13 (-1.39%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
